Development of a new pharmacotherapy for heart failure using alpha-2 adrenergic agonists
Project/Area Number |
15K09110
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cardiovascular medicine
|
Research Institution | National Cardiovascular Center Research Institute |
Principal Investigator |
SHIMIZU Shuji 国立研究開発法人国立循環器病研究センター, 研究所, 研究員 (80443498)
|
Co-Investigator(Renkei-kenkyūsha) |
KAWADA Toru 国立研究開発法人国立循環器病研究センター, 研究所, 室長 (30243752)
AKIYAMA Tsuyoshi 国立研究開発法人国立循環器病研究センター, 研究所, 客員研究員 (70202554)
|
Research Collaborator |
FUKUMITSU Masafumi
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 心不全 / α2アドレナリン受容体作動薬 / デクスメデトミジン / 心臓交感神経 / 心臓迷走神経 / α2アドレナリン受容体作動薬 |
Outline of Final Research Achievements |
Animal experiments were performed to investigate therapeutic effects of alpha-2 adrenergic agonist-induced cardiac vagal activation on chronic heart failure. Ninety days survival was observed in doxorubicin-induced cardiomyopathy mice treated with dexmedetomidine or guanfacine. Because both alpha-2 adrenergic agonists did not improve 90 days survival in mice, several acute experimental studies using normal rats were added. These studies revealed that alpha-2 adrenergic agonists centrally suppressed cardiac sympathetic nerve activity but increased peripheral vascular resistance. Therefore, therapeutic benefits of alpha-2 adrenergic agonists on chronic heart failure may be dependent on the balance between sympatholytic effect and increased ventricular afterload in addition to cardiac vagal enhancement.
|
Report
(4 results)
Research Products
(26 results)